Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI

NCT01605344 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was withdrawn due to lack of patient enrollment.

Conditions

Advanced Adenocarcinoma of the Colon or Rectum

Interventions

DRUG: FOLFIRI.
DRUG: Atorvastatin

Sponsor

UNC Lineberger Comprehensive Cancer Center